Faculty: Relationships with financial sponsors: Speakers Bureau/Honoraria: Advisory board/consulting Fees:
|
|
- Timothy Cooper
- 5 years ago
- Views:
Transcription
1 Faculty/Presenter Disclosure Faculty: Joss de Wet Relationships with financial sponsors: Speakers Bureau/Honoraria: Gilead, ViiV, Merck. Advisory board/consulting Fees: Gilead, ViiV, Merck. Dr Joss de Wet Clinical Assistant Professor Family Medicine UBC Mitigating Potential Bias Discuss principles and not specific drugs Follow guidelines Only one drug approved for PREP, namely Truvada which now is generic PREP Present BC program & stastistics Evidence Daily vs Ondemand How to apply, follow STD BC program Truvada (generic) covered as of Jan 2018 September: n = 2490 Prescribers: n = 49 Zero HIV infections 3 4 Why PREP? New infections in all risk groups have declined except MSM STD rates increasing in MSM Condom use at best is 70% 6 1
2 VAX004 study: HIV vaccine study EXPLORE study: Largest behavioural HIV prevention N = 772 men VAX: Per one act: No condom use 1:90 to 100% condom use 1:667 EXPLORE Per one act: No condom use 1:244 to 100% condom use 1: 44 Real life setting 70% efficacy Long term consistent condom use very difficult 13% able to maintain 100% condom use over 3 years cosmith DK, Herbst JH, Zhang XJ, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men (MSM) in the US. J Acquir Immune Defic Syndr, e-publication ahead of print. Doi: /QAI December PROUD: Pragmatic Open-Label Randomized Trial of Pre-Exposure Prophylaxis mitt a efficacy of % Adherence-adjusted efficacy reduction in acquisition based on TDF detection in blood Clinical Participants Number Drug of HIV infection b c trial (9% % % (9% CI) CI) Men who have iprex 2499 TVD* 42 (18-60) 92 (40-99) sex with men TDF 67 (44-81) 86 (67-94) Partners HIV discordant 4747 PrEP couples TVD* 7 (-87) 90 (8-98) Heterosexually TDF 2 active men and 1200 TVD* 62 (22-83) 84 NS women Bangkok Tenofovir IDU 2413 TDF 49 (10-72) 74 (2-91) Study Heterosexually Fem-PrEP 191 TVD* NS < 40% active women Heterosexually VOICE 029 TVD* NS <30% active women a. Modified Intent to Treat b. Excluded only those enrolled patients later found to be infected at randomization and those with no follow-up visit or HIV test 11 c. The percentage of reduction in HIV incidence among those with TFV detected in blood, compared with those without detectable TFV *TVD = FTC/TDF High-risk, HIV-uninfected MSM engaging in CAI N=44 PROUD Immediate (IMM) TVD (n=27) Deferred (DEF) TVD (start at Month 12) (n=269) Primary endpoint: HIV seroconversion between randomisation and Month 12 Secondary endpoints: Randomised, multicentre, open-label pilot study in the UK All subjects received comprehensive HIV prevention services, including condoms, riskreduction counseling, testing and treatment for sexually transmitted infections, and HIV preand post-test counseling Safety, adherence, sexual behavior, resistance development Oct 2014: the PROUD Trial Steering Committee announced that participants on the deferred arm of the study, who had not yet started PrEP, would be offered the opportunity to begin PrEP ahead of schedule McCormack S. & al. Lancet 2016;387,3-60 ClinicalTrials.gov Identifier: NCT CAI: Condomless anal intercourse 12 2
3 PROUD: Pragmatic Open-Label Randomised Trial of Pre-Exposure Prophylaxis Use of post-exposure prophylaxis by arm: IMM: 12 subjects (4.4%); 14 prescriptions DEF: 8 subjects (31.%); 174 prescriptions HIV Incidence Efficacy results Group Infections, n Follow-up (PY) Incidence/100 person-years (90% CI) Overall * Immediate ( ) Deferred ( ) 86% (90% CI: 64-96) Relative Risk Reduction; p= Number needed to treat to avert one HIV infection = 13 (90% CI: 9-23) McCormack S. & al. Lancet 2016;387,3-60 * The overall incidence was 4.9 infections/100 person-years, 90%CI ( ) at 1 st communication in McCormack S, et al. CROI 201; Seattle, WA. #22LB 13 IPERGAY: High-risk, HIV-uninfected MSM with Condomless anal sex with 2 partners within 6 months N=400 egfr > 60 ml/min Primary endpoint: Secondary endpoints: ONDEMAND PREP Randomised, multicentre, double-blind study in France and Québec On-demand regimen constitutes: 2 TVD or 2 placebo 2-24 hrs prior to sexual intercourse exposure 1 TVD or placebo 24 hrs after first intake 1 TVD or placebo 48 hrs after first intake HIV seroconversion «On-demand» TVD (n=199) «On-demand» TVD placebo (n=201) Sexual behavior, safety events, adherence Oct. 2014, the DSMB recommended that the placebo arm be discontinued and patients be offered switching into the treatment arm. Molina JM et al. CROI 201; Seattle, WA. #23LB Molina JM & al. N Engl J Med 201;373, IPERGAY : Sex-Driven iprep FTC/TDF is only licensed as a daily dosage for PrEP All participants received a package of preventative measures: counseling repeated HIV testing screening & treatment for other STIs HBV and HAV vaccination condoms and gel IPERGAY : Sex-Driven iprep IPERGAY : Sex-Driven iprep Efficacy results 2 tablets (TDF/FTC or placebo) 2-24 hours before sex 1 tablet (TDF/FTC or placebo) 24 hours later 1 tablet (TDF/FTC or placebo) 48 hours after first intake 16 subjects infected Placebo = 14 (incidence: 6.60/100 PY) FTC/TDF =2 (incidence: 0.91/100 PY) Mean follow-up= 9.3 months (IQR ) Average 1 pills / month (TVD : IQR 11-21; PBO : IQR 9-21) 6 subjects received post-exposure prophylaxis : PBO = 2 p=0.37 TVD = 31 Friday Saturday Sunday Monday Tuesday Wednesday Thursday Friday Saturday Sunday 4 pills of TDF/FTC taken over 3 days to cover one sexual intercourse 86% (9% CI: 40-98, p=0.002) Relative Risk Reduction Number needed to treat for 1 year to avert 1 HIV infection: 18 (9% CI : 11- Molina JM et al. CROI 201; Seattle, WA. #23LB Molina JM & al. N Engl J Med 201;373, ) 16 FTC/TDF is only licensed as a daily dosage for PrEP Conclusions On Demand oral PrEP with TDF/FTC was very effective with a 86% (9% CI: 40-99) reduction in HIV-incidence Adherence was good Safety of on demand TDF/FTC was overall similar to placebo except for gastrointestinal AEs No evidence of risk compensation ANRS Prevenir: Daily vs On-Demand TDF/FTC Oral PrEP Multicenter, open-label, prospective cohort study in Paris HIV-negative adults at high risk of HIV infection with inconsistent condom use; CrCl 0 ml/min; HBsAg negative in on-demand arm (N = 194)* Beginning of Study May 3, 2017 Daily TDF/FTC PrEP (n = 724) On-Demand TDF/FTC PrEP (2-1-1: 2 doses before sex, 1 dose QD for 2 days after sex) (n = 870) *Participants enrolled in arm of their choice with ability to switch; target enrollment, N = 3000 (8% MSM). Plus condoms, gels, risk reduction and adherence counseling, questionnaire on sexual behavior. Follow-up every 3 mos with STI and/or HIV testing, plasma creatinine measurement. Current Analysis July 2, 2018 End of Study May 31, 2020 Predominantly MSM (98.8%), white (8.2%); median age: 36 yrs Primary endpoint: 1% reduction in new HIV diagnoses among MSM in Paris vs rate reported by National Surveillance network in 2016 Secondary endpoints: PrEP adherence, sexual behavior, safety Molina J-M, et al. AIDS Abstract WEAE0406LB. 3
4 ANRS Prevenir: HIV Incidence Primary Endpoint HIV incidence/100 PY (9% CI) Mean follow-up: 7 mos Daily PrEP (443 PYFU) On-Demand PrEP* (06 PYFU) 0 (0-0.8) 0 (0-0.7) Overall HIV infections averted, n = 8 Assuming incidence of 9.17/100 PY as reported for ANRS IPERGAY study among participants in Paris Overall incidence of study discontinuation: 3.3/100 PY, including PrEP discontinuations of 1./100 PY Molina J-M, et al. AIDS Abstract WEAE0406LB. *On-demand PrEP strategy not FDA approved. Slide credit: clinicaloptions.c At Last Sexual Encounter, n (%) PrEP use Total Correct* ANRS Prevenir: PrEP Adherence, Sexual Behavior, Safety Daily PrEP (1088 Acts) 1068 (98.2) 1024 (9.8) On-Demand PrEP (1191 Acts) 967 (81.2) 931 (96.2) Condom use 206 (18.9) 28 (21.6) Incidence/10 0 PY (9% CI) Drug-related AEs Daily PrEP (443 PYFU) 11. ( ) Median episodes of condomless sex in previous 4 wks: 3-6 with daily PrEP, Grade ( with on-demand PrEP creatinine 19.7) Median sexual partners in CrCl (11.7- previous ml/min 19.2) 3 mos: 10-1 with daily PrEP, 6-10 with on-demand PrEP Most drug-related AEs were On-Demand PrEP (06 PYFU) 12. ( ) Grade 3/4 AEs 3.6 (2.1-.9) 4.7 ( ) Viral hepatitis 1.1 ( ) 1.2 ( ) ALT abnormality Grade 3/4 4.6 ( ) 2.3 ( ) 40.3 ( ) 2.0 ( ) 17.6 ( ) 17.6 ( ) Participants with adherence data, n = gastrointestinal *Per protocol, or at least 1 pill before and after within 24 hrs. No discontinuations due to drug-related Molina J-M, et al. AIDS Abstract WEAE0406LB. AEs Slide credit: clinicaloptions.c BC-CfE PrEP Enrolment & Prescription Request Form 1. Their identifiers 2. Your identifiers/location for Pickup 3. HIV Risk Category 4. Baseline Blood work Current negative HIV Ag/Ab test (within previous 1 days), egfr 60mL/min, Hepatitis B surface antigen status. Prior PrEP 6. Prescription quantity Initial Script: 30 days Prior PrEP: 90 days 4
5 PrEP Monitoring Baseline: HIV, renal, urine ACR, Hep B/C Serology, STI screen Start prescription for 30 days First Follow-up: Just before end of first month of use Check HIV, renal function again Get prescription refill: 90 days Every 3 months HIV/renal/STI checks STI screening We recommend STI screens q3months US PrEP demonstration project: 0.9% STI during followup If screening had been conducted only semi-annually or based on symptoms, 62 (34.3%) of participants with GC, 86 (41.0%) of participants with CT and 11 (20.4%) of participants with syphilis would have been missed, extending the period of infectivity by up to 3 months/case. Cohen, S. CROI 2016 Abstract 870. BC CfE PrEP Guidelines 2017 PrEP refills Book followup and review blood work prior to each fill easiest if scheduled a week before medications to run out Confirm HIV negative, adequate renal function, other STI monitoring A new signed prescription required for each fill Pre-printed PrEP refill form (sent automatically to prescriber) or any legal prescription format Nurse practitioners can be designated to refill 90 day maximum refill Fax and Allow at least business days for preparation Refill must be picked up within 30 days of prescription date PrEP monitoring Renal safety assessment of 2499 HIV-negative subjects in iprex study A mild, non-progressive decrease in Mean Change in CrCL (ml/min) creatinine clearance (Cockcroft-Gault), that was reversible and readily managed with routine monitoring Did not vary by race, age, or HTN history Affected by NSAID use -3.4 ml/min (+NSAID) vs ml/min (no NSAID), P = 0.04 Wk 4 At Stop Post-stop FTC/TDF Placebo P-value Change in Creatinine Clearance from Baseline (ml/min)* 0 10 FTC/TDF Placebo 2 9 * in 1,137 subjects Week Solomon M, et al. CROI 2013; Atlanta, GA. #998 30
6 Do not use daily TRUVADA in HIV-uninfected individuals for PrEP if CrCl is below 60 ml/min. If a decrease in CrCl is observed in uninfected individuals while using TRUVADA for PrEP, evaluate potential causes and re-assess potential risks and benefits of continued use. Routine monitoring of estimated creatinine clearance, serum phosphorus, urine glucose, and urine protein should be performed in all individuals with mild renal impairment. If a decrease in estimated creatinine clearance is observed in uninfected individuals while using TRUVADA for PrEP, evaluate potential causes and re-assess potential risks and benefits of continued use Renal impairment, including cases of acute renal failure and Fanconi syndrome, has been reported in association with the use of VIREAD. TRUVADA should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple NSAIDs) Do not use TRUVADA in HIV-uninfected individuals for PrEP if CrCl is below 60 ml/min. If a decrease in CrCl is observed in uninfected individuals while using TRUVADA for PrEP, evaluate potential causes and re-assess potential risks and benefits of continued use. Routine monitoring of estimated creatinine clearance, serum phosphorus, urine glucose, and urine protein should be performed in all individuals with mild renal impairment. If a decrease in estimated creatinine clearance is observed in uninfected individuals while using TRUVADA for PrEP, evaluate potential causes and re-assess potential risks and benefits of continued use Renal impairment, including cases of acute renal failure and Fanconi syndrome, has been reported in association with the use of VIREAD. TRUVADA should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple NSAIDs) Do not use TRUVADA in HIV-uninfected individuals for PrEP if CrCl is below 60 ml/min. If a decrease in CrCl is observed in uninfected individuals while using TRUVADA for PrEP, evaluate potential causes and re-assess potential risks and benefits of continued use. Routine monitoring of estimated creatinine clearance, serum phosphorus, urine glucose, and urine protein should be performed in all individuals with mild renal impairment. If a decrease in estimated creatinine clearance is observed in uninfected individuals while using TRUVADA for PrEP, evaluate potential causes and re-assess potential risks and benefits of continued use Renal impairment, including cases of acute renal failure and Fanconi syndrome, has been reported in association with the use of VIREAD. TRUVADA should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple NSAIDs) Do not use TRUVADA in HIV-uninfected individuals for PrEP if CrCl is below 60 ml/min. If a decrease in CrCl is observed in uninfected individuals while using TRUVADA for PrEP, evaluate potential causes and re-assess potential risks and benefits of continued use. Routine monitoring of estimated creatinine clearance, serum phosphorus, urine glucose, and urine protein should be performed in all individuals with mild renal impairment. If a decrease in estimated creatinine clearance is observed in uninfected individuals while using TRUVADA for PrEP, evaluate potential causes and re-assess potential risks and benefits of continued use Renal impairment, including cases of acute renal failure and Fanconi syndrome, has been reported in association with the use of VIREAD. TRUVADA should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple NSAIDs)
7 Change from baseline, % 9/28/ P l a ce b o FT C/ T DF Spine (L1-L4) P = P = P = Mean, SE and P-values by linear mixed model Total Hip Week Week P l a ce bo FT C/ T D F Small but significant decreases in BMD at the spine, but not the hip, were observed in HIV-negative men randomized to FTC/TDF relative to placebo There were no differences in bone fractures between the groups (P=0.41) P l a ce b o FT C/ T DF P < P = P = 0.40 Mulligan K, et al. CROI Boston. # 94LB 37 In iprex, mean number of partners decreased and condom use increased over time 1,2 In Partners PrEP, unprotected sex decreased over time 3 1. Grant R, et al. CROI Boston. Oral # Grant R, et al. N Engl J Med 2010;30: Baeten J, et al. IAS 2011; Rome. Oral #MOAX Study iprex (36 on FTC/TDF, 64 on 1. Grant R, et al. N Engl J Med 2010;30: Lehman D, et al. CROI 2014; Boston. #90LB 3. Thigpen M, et al. N Engl J Med 2012;367: Van Damme L, et al. N Engl J Med 2012;367: Parikh, et al. CROI 2014; Boston. #94 Infected on Study Resistant to Infected, n FTC or TDF, n placebo) 103 Partners PrEP *2 (21 on FTC/TDF, 30 on TDF, 2 on placebo) TDF (9 on FTC/TDF, 24 on placebo) FEM-PrEP 4 68 (33 on FTC/TDF, 3 on placebo) None 3 on FTC/TDF (2 M184I/V, 1 M184I/V + K6R) * ; 1 on TDF (M184I/V); 2 on placebo (M184I/V) 1 on placebo (K6R <1%) 1 on placebo (M184V)*; 4 on FTC/TDF (M184V/I) VOICE on FTC/TDF (M184V/I) Unrecognized Baseline Infections d Infected, n 10 (2 on FTC/TDF, 8 on placebo) 18 (4 on FTC/TDF, 8 on TDF, 6 on placebo) 3 (1 on FTC/TDF, 2 on placebo) (1 on FTC/TDF, 4 on placebo) Resistant to FTC or TDF, n 2 on FTC/TDF (M184V/I); 1 on placebo (M184V) * 2 on FTC/TDF (M184V); 1 on TDF (K6R/K70E) 1 on FTC/TDF (K6R, M184V, A62V) Resistance development was rare but likely to occur when PrEP was given during unrecognized/acute infection None 22 2 on FTC/TDF (M184V) * Using ultra-deep sequencing Transmitted (primary) resistance can occur independent of PrEP, which likely explains resistance in the placebo arm 1 probable and 2 possible transmitted resistance; 1 uncertain timing of infection (HIV RNA detectable at first follow-up visit) Infection + incomplete suppression of replication by FTC/TDF selects resistance; transmitted (primary) resistance can occur, independent of PrEP, which likely explains resistance in the placebo arm 39 Conclusions We have the tools for HIV elimination expanding ART uptake and PrEP PrEP must be integrated into sexual health and primary care services as a component of HIV Prevention programming for MSM and other populations at risk Need to evaluate mechanisms to identify at-risk individuals and linkage to care STI services as entry point HIV testing services Develop linkages to primary care if PrEP not offered on-site 7
Moving beyond condoms to prevent HIV transmission. Are you Prepared for HIV PrEP?
Moving beyond condoms to prevent HIV transmission Are you Prepared for HIV PrEP? The Issues New HIV infections in the US continue Vast majority of infections are sexually acquired Condoms work but are
More informationCROI 2015: HIV Prevention Updates
NORTHWEST AIDS EDUCATION AND TRAINING CENTER CROI 2015: HIV Prevention Updates Ruanne V Barnabas, MBChB Dphil Global Health and Medicine University of Washington a bevy of new studies quelled most remaining
More informationThe Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN
The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN 1 Ongoing HIV transmission despite expanding access to ART SA 18 16 14 12 10 8 6 4 2 0 Treatment exposure
More informationDrug development in relation to PrEP and the PROUD study
Drug development in relation to PrEP and the PROUD study David Dolling Medical Statistician MRC Clinical Trials Unit 18 th October 2012 What is PrEP? - Pre-exposure Prophylaxis A strategy that uses antiretrovirals
More informationPrEP Dosing Strategies
PrEP Dosing Strategies Outline o Background PrEP absorption and tissue penetration o Oral versus topical o Lead in and lead out dosing Time to protection o Cycling on and off PrEP o Balancing toxicity
More informationPrEP efficacy the evidence
PrEP efficacy the evidence Dr Michael Brady Consultant, HIV and Sexual Health King s College Hospital, London Medical Director Terrence Higgins Trust PrEP Pre-exposure prophylaxis Tenofovir and emtricitabine
More informationHot Topics Adult Infectious Diseases 2018 Wayne Ghesquiere MD FRCPC
Hot Topics Adult Infectious Diseases 2018 Wayne Ghesquiere MD FRCPC Infectious Diseases Consultant Island Health Authority Clinical Assistant Prof of Med, UBC Victoria Faculty/Presenter Disclosure Wayne
More informationAntiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?
Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Lut Van Damme 11 Oct 2012 1 Disclaimer Gilead donated the study product for the FEM-PrEP trial I participated
More informationPre-Sexual Exposure Prophylaxis (PrEP)
Projeto Praça Onze Universidade Federal do Rio de Janeiro Pre-Sexual Exposure Prophylaxis (PrEP) Mauro Schechter Principal Investigator, Projeto Praça Onze Professor of Infectious Diseases Universidade
More informationBiomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
More informationCase Studies in PrEP Management. Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016
Case Studies in PrEP Management Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016 Continuing Medical Education Disclosure Program Faculty: Kevin
More informationHIV Pre-Exposure Prophylaxis (PrEP)
HIV Pre-Exposure Prophylaxis (PrEP) A Crash Course For General Practitioners Vincent Cornelisse BSc(Hons) MBBS FRACGP FAChSHM(RACP) Sexual Health Physician Prahran Market Clinic & Melbourne Sexual Health
More informationDominic Chow, MD, PhD, MPH, Hawaii Center for AIDS Kunane Dreier, Prevention, Life Foundation Kekoa Kealoha, Hawaii Island HIV/AIDS Foundation Alexis
Dominic Chow, MD, PhD, MPH, Hawaii Center for AIDS Kunane Dreier, Prevention, Life Foundation Kekoa Kealoha, Hawaii Island HIV/AIDS Foundation Alexis Charpentier, Harm Reduction Services Branch, Hawaii
More informationDisclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.
Disclosure PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION I have no financial interest in and/or affiliation with any external organizations in relation to this CE program. DaleMarie Vaughan, PharmD
More informationRoy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City
PrEP 2013 Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Slide #2 U.S.: New HIV Infections Per Year ~50,000
More informationHIV Pre-Exposure Prophylaxis (PrEP)
HIV Pre-Exposure Prophylaxis (PrEP) Disclosures No disclosures to report Carlos Malvestutto, MD, MPH Assistant Professor, Internal Medicine Division of Infectious Diseases The Ohio State University College
More informationPrEP for HIV prevention. Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint
PrEP for HIV prevention Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint DISCLOSURES I have received a research grant from Gilead Sciences awarded to my institution I have
More informationHIV Pre-Exposure Prophylaxis (PrEP)
HIV Pre-Exposure Prophylaxis (PrEP) Carlos Malvestutto, MD, MPH Assistant Professor, Internal Medicine Division of Infectious Diseases The Ohio State University College of Medicine Disclosures No disclosures
More informationGetting Prepped for PrEP. Ken Ho, MD, MPH World AIDS Day
Getting Prepped for PrEP Ken Ho, MD, MPH World AIDS Day Objectives HIV epidemiology What is PrEP? Does it Work? Who gets PrEP? How do I prescribe PrEP What to do at the first visit? What to do at follow
More informationReady, set, PrEP! Renee-Claude Mercier PharmD, PhC, BCPS-AQ ID, FCCP Professor of Pharmacy and Medicine University of New Mexico
Ready, set, PrEP! Renee-Claude Mercier PharmD, PhC, BCPS-AQ ID, FCCP Professor of Pharmacy and Medicine University of New Mexico Objectives At the end of the talk the audience should be able to: Understand
More informationPrEP: Pre Exposure Prophylaxis
PrEP: Pre Exposure Prophylaxis Lyn Stevens, NP, MS, ACRN Deputy Director Office of the Medical Director NYS Department of Health, AIDS Institute Faculty Disclosure Lyn Stevens No relationships to disclose
More informationPre-exposure Prophylaxis for HIV Prevention
Mountain West AIDS Education and Training Center Pre-exposure Prophylaxis for HIV Prevention Concerns about PrEP: Sexual Behavior and STIs Joanne Stekler, MD MPH May 19, 2016 This presentation is intended
More informationPros and Cons of on demand PrEP «Pros» Laurent COTTE, MD Infectious Diseases Department Croix-Rousse Hospital, Lyon - France
Pros and Cons of on demand PrEP «Pros» Laurent COTTE, MD Infectious Diseases Department Croix-Rousse Hospital, Lon - France Disclosures Consulting fees : Mlan, Gilead Fees for non-cme/ce services : BMS,
More informationPrEP in the Real World: Clinical Case Studies
PrEP in the Real World: Clinical Case Studies Kevin L. Ard, MD, MPH April 30, 2015 Massachusetts General Hospital, National LGBT Health Education Center Continuing Medical Education Disclosure Program
More informationEmtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers
Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers About emtricitabine/tenofovir disoproxil fumarate for HIV-1 PrEP
More informationImportant Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. For Healthcare Providers
Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication For Healthcare Providers About TRUVADA for a PrEP Indication INDICATION AND PRESCRIBING CONSIDERATIONS TRUVADA,
More informationREVIEW OF PREP GUIDELINES: A PRIMER FOR THE PRIMARY CARE PRACTITIONER ANTONIO E. URBINA, MD. PrEP Webinar Series
REVIEW OF PREP GUIDELINES: A PRIMER FOR THE PRIMARY CARE PRACTITIONER ANTONIO E. URBINA, MD PrEP Webinar Series Disclosure Speaker s Bureau: Gilead, VIIV, BMS, Merck, Serono LEARNING OBJECTIVES: 1. Review
More informationImportant Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP)
Important Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) For Healthcare Providers About Emtricitabine/Tenofovir Disoproxil
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationPre exposure Prophylaxis (PrEP): Stepping Up HIV Prevention
Pre exposure Prophylaxis (PrEP): Stepping Up HIV Prevention Dawn K. Smith, MD, MS, MPH Centers for Disease Control and Prevention The findings and conclusions in this presentation have not been formally
More information10/05/2016. PrEP : from proof of concept to real life. E. CUA Nice university hospital
PrEP : from proof of concept to real life E. CUA Nice university hospital 1 Disclosures Received honoraria and acted as consultant : Merck, Gilead, ViiV Co-investigator: Merck, Gilead, ViiV and BMS phase
More informationPre-Exposure Prophylaxis (PrEP) and the Governor s Plan to End AIDS: What Every Clinician Needs to Know
Pre-Exposure Prophylaxis (PrEP) and the Governor s Plan to End AIDS: What Every Clinician Needs to Know ANTONIO E. URBINA, MD Medical Director Associate Professor of Medicine Mt. Sinai Hospital Disclosure
More informationGuidelines for PrEP in PWID
Guidelines for PrEP in PWID Any use of injection drugs (past 6 months) AND Any sharing of injection equipment OR participation in methadone, naloxone, or buprenorphine treatment program (past 6 months)
More informationTRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. Training Guide for Healthcare Providers
TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication Training Guide for Healthcare Providers About TRUVADA for a PrEP indication to reduce the risk of sexually acquired HIV-1 infection in high-risk
More informationLessons from MSM PrEP pilots / demonstration projects. Kevin Rebe
Lessons from MSM PrEP pilots / demonstration projects Kevin Rebe rebe@anovahealth.co.za PrEP Demonstration Projects US: Multisite demonstration project in San Francisco, Miami and Washington DC. South
More informationPre-exposure prophylaxis : Systemic and topical. Linda-Gail Bekker The Desmond Tutu HIV Centre UCT SA HIV ClniciansSociety Conference 2012
New biomedical technologies. Pre-exposure prophylaxis : Systemic and topical. Linda-Gail Bekker The Desmond Tutu HIV Centre UCT SA HIV ClniciansSociety Conference 2012 And the last parachute goes to..
More informationPre-Exposure Prophylaxis (PrEP) for HIV Infection
Pre-Exposure Prophylaxis (PrEP) for HIV Infection Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health University of California Los Angeles Attending Physician UCLA Center AIDS Research
More informationPRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program
PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program Disclosures None Objectives Review the evidence regarding the
More informationIncidence des IST chez les PrEPeurs
Incidence des IST chez les PrEPeurs Jean-Michel Molina Hopital Saint-Louis, Université de Paris Diderot, Inserm U941, Paris, France PrEP, IST et Santé Sexuelle, 29 Mars 2018, Paris La PrEP en France Début
More informationPrEP for Women: HIV Prevention in Family Planning Settings
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention PrEP for Women: HIV Prevention in Family Planning Settings Dawn K. Smith, MD, MS, MPH Division of HIV/AIDS Prevention dsmith1@cdc.gov
More informationPEP and PREP. Dr David Hawkins Chelsea and Westminster Hospital
PEP and PREP Dr David Hawkins Chelsea and Westminster Hospital Opportunities for biomedical interventions YEARS HOURS 72 HOURS YEARS Prior to exposure Exposure (pre-coital/ coital) Exposure (pre-coital/
More informationUpdate on Biomedical Prevention. Thomas C. Quinn, MD, MSc
Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health
More informationPre-exposure Prophylaxis and Primary Care
Pre-exposure Prophylaxis and Primary Care National Latino HIV and Hepatitis C Conference June 7 th, 2016 Allison Finkenbinder, MSN, WHNP-BC Denver Prevention Training Center Who s in the audience? Disclosures
More informationPre-exposure Prophylaxis. Robert M Grant October 2014
Pre-exposure Prophylaxis Robert M Grant October 2014 The HIV Pandemic 2.3 Million New HIV Infections in 2012 39% in Young People (ages 15-24) The HIV Pandemic 1.6 Million Started Therapy in 2012 1.4 New
More informationThe role of Integrase Inhibitors during HIV prevention
The role of Integrase Inhibitors during HIV prevention Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint 2nd Global HIV Clinical Forum: Integrase Inhibitors Paris July 22th
More informationThe Door is Open PrEP in Practice. Antonio E. Urbina, MD Associate Professor of Medicine Icahn School of Medicine Mount Sinai Hospital
The Door is Open PrEP in Practice Antonio E. Urbina, MD Associate Professor of Medicine Icahn School of Medicine Mount Sinai Hospital Learning Objectives As a result of participating in this activity,
More informationFaculty/Presenter Disclosure. HIV Update Outline. Undetectable = Untransmissable HTPN 052. Partner Opposites attract 9/28/2018
Faculty/Presenter Disclosure HIV Update 2018 Dr. Joss de Wet Clinical Assistant Professor Family Medicine UBC Faculty: Joss de Wet Relationships with financial sponsors: Speakers Bureau/Honoraria: Gilead,
More informationART and Transmission. Martin Fisher. Brighton and Sussex University Hospitals, UK
ART and Transmission Martin Fisher Brighton and Sussex University Hospitals, UK 11th Advanced HIV Course Aix-en-Provence 2013 New HIV diagnoses by exposure group: United Kingdom, 2002 2011 1 Predicted
More informationPrEP for HIV Prevention. Adult Clinical Guideline from the New York State Department of Health AIDS Institute
PrEP for HIV Prevention Adult Clinical Guideline from the New York State Department of Health AIDS Institute www.hivguidelines.org Purpose of the PrEP Guideline Raise awareness of PrEP among healthcare
More informationWhere are we going after effectiveness studies?
Where are we going after effectiveness studies? Nyaradzo M. Mgodi (MBChB, MMed) UZ-UCSF Collaborative Research Program Harare, Zimbabwe MTN Annual Meeting 28 March 2011, Arlington, VA Introduction 30 years
More informationSouth African Guidelines for the Safe Use of. Dr. Oscar Radebe
South African Guidelines for the Safe Use of PrEP in MSM Dr. Oscar Radebe Background Globally MSM(men who have sex with men) have been disproportionately at high risk of HIV transmission. Biological &
More informationGilead Announces Data Demonstrating Non-Inferiority of Once-Daily Descovy vs. Once-Daily Truvada for Prevention of HIV Infection
Gilead Announces Data Demonstrating Non-Inferiority of Once-Daily Descovy vs. Once-Daily Truvada for Prevention of HIV Infection March 6, 2019 DISCOVER Trial Meets Primary and Secondary Endpoints and Will
More informationHIV Reproductive Health: Conception Options in the Era of PrEP
HIV Reproductive Health: Conception Options in the Era of PrEP Meg Sullivan, MD Director, HIV Clinical Programs, Section of Infectious Diseases Boston Medical Center Boston University School of Medicine
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationPROACTIVE HIV PREVENTION WITH TRUVADA FOR PrEP
PROACTIVE HIV PREVENTION WITH TRUVADA FOR PrEP Please see full Prescribing Information, including BOXED WARNING on risk of drug resistance with use of TRUVADA for PrEP in undiagnosed early HIV-1 infection
More informationHIV & Condomless Sex - What is the Risk? Why Not? Alan J. Taege, MD Assistant Professor of Medicine Department of Infectious Disease Cleveland Clinic
HIV & Condomless Sex - What is the Risk? Why Not? Alan J. Taege, MD Assistant Professor of Medicine Department of Infectious Disease Cleveland Clinic Yes No What s Going on Out There? Condomless Sex among
More information11/7/2016. Jeanne M. Marrazzo, MD, MPH Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama
HIV Preexposure Prophylaxis: Pills, Rings, Injectables, and Gels Oh My! Jeanne M. Marrazzo, MD, MPH Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FORMATTED: 10/17/16 Financial
More informationOR: Steps you can take in the clinic to prevent HIV infections
Implementing Changes to Reduce HIV Incidence: Synergies between Public Health and Primary Care Kevin Ard, MD, MPH Brigham and Women s Hospital, Massachusetts General Hospital, and the Fenway Institute
More informationHIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland. An update for registered practitioners September 2017
HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland An update for registered practitioners September 2017 Key Messages HIV is a major public health challenge for Scotland with an annual average of 359
More informationHIV. The Role of Pre-Exposure Prophylaxis (PrEP) for the Prevention of HIV. Brief History of HIV AIDS. Global HIV Infection.
The Role of Pre-Exposure Prophylaxis (PrEP) for the Prevention of HIV HIV Sarah Kemink, PharmD, AAHIVP WMSHP Spring Seminar 5/05/2015 AIDS CD4 less than 200 +/- AIDS-defining illness Most common: Candidiasis
More informationUpdate on ARV based PrEP
Update on ARV based PrEP Z Mike Chirenje MD FRCOG University of Zimbabwe, College of Health Sciences, Dept. of Obstetrics and Gynaecology Avondale, Harare, Zimbabwe chirenje@uz-ucsf.co.zw Controlling HIV
More informationCombination HIV Prevention Research Carl W. Dieffenbach, Ph.D.
Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID, NIH October 13, 2011 Multiple strategies needed to assemble a wellrounded prevention toolkit Know the epidemics
More informationemtricitabine/tenofovir disoproxil 200mg/245mg film-coated tablets (Truvada ) SMC No. (1225/17) Gilead Sciences Ltd
emtricitabine/tenofovir disoproxil 200mg/245mg film-coated tablets (Truvada ) SMC No. (1225/17) Gilead Sciences Ltd 10 March 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationHIV Prevention among Women
HIV Prevention among Women Assistant Professor of Medicine Division of Infectious Diseases Baylor College of Medicine Disclosures: Gilead Sciences - Scientific Advisory Board; Investigatorinitiated research
More informationThe HIV Prevention Pill: The State of PrEP Science and Implementation. James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE
The HIV Prevention Pill: The State of PrEP Science and Implementation James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE Overview 1. The Basics 2. A review of the science 3. An update
More informationDr Michelle Hanlon Consultant physician, Genitourinary Medicine. Olafiaklinikken, Oslo University Hospital. National Advisory Unit for STIs
Dr Michelle Hanlon Consultant physician, Genitourinary Medicine Olafiaklinikken, Oslo University Hospital. National Advisory Unit for STIs Truvada FDA approved PrEP 2012 Initial slow uptake now over 120,000
More informationPREPARING FOR PREP: FROM KEY POPULATIONS THEORY TO PRACTICE. Dr Oscar Radebe
PREPARING FOR PREP: FROM THEORY TO PRACTICE KEY POPULATIONS Dr Oscar Radebe PrePARINGFOR THE END OF HIV Until recently there has been exciting new advances in clinical research focusing on HIV prevention
More informationUK community perspective on PrEP and PROUD. Simon Collins
UK community perspective on PrEP and PROUD Simon Collins Overview Community perspective on PrEP: 3 myths and 5 community issues (Glasgow) The PROUD study and UK experience Update from CROI - February 2015
More informationPre-Exposure Prophylaxis (PrEP): Best Practices for Pharmacists
Pre-Exposure Prophylaxis (PrEP): Best Practices for Pharmacists Tina J Kanmaz, PharmD, AAHIVE Associate Clinical Professor Assistant Dean, Experiential Pharmacy Education St. John s University College
More informationRecent Breakthroughs in HIV Prevention for Men who Have Sex with Men and Transgender Populations
Recent Breakthroughs in HIV Prevention for Men who Have Sex with Men and Transgender Populations Kevin Ard, MD, MPH Brigham and Women s Hospital The Fenway Institute Boston, MA Funding: The New England
More informationFind both sets of guidelines on nyc.gov by searching HIV PrEP and PEP. Per CDC Guidelines, PrEP may be appropriate for the following populations:
PrEP Provider FAQs 1. What is PrEP? PrEP is short for pre-exposure prophylaxis. It is the use of antiretroviral medication to prevent acquisition of HIV infection. PrEP is used by HIV uninfected people
More informationAttendees will be able to:
A. Kay Kalousek, DO, MS, FACOFP kaysdroid@gmail.com April 21, 2017 Attendees will be able to: List strategies for prevention of HIV infection Explain the pharmacology of TDF/FTC related to PrEP Assess
More informationPrEP and npep for HIV Prevention. Harry Rosado-Santos MD, FACP Associate Professor UU School of Medicine
PrEP and npep for HIV Prevention Harry Rosado-Santos MD, FACP Associate Professor UU School of Medicine Case Study A 26 y/o M presents for routine asymptomatic screening for sexually transmitted infections
More informationFertility Desires/Management of Serodiscordant HIV + Couples
Fertility Desires/Management of Serodiscordant HIV + Couples William R. Short, MD, MPH Assistant Professor of Medicine Division Of Infectious Diseases Jefferson Medical College of Thomas Jefferson University
More informationPre-Exposure Prophylaxis for HIV prevention: what we know and what we can do
Pre-Exposure Prophylaxis for HIV prevention: what we know and what we can do Bertrand Lebouché MD PhD Chronic Viral Illness Service, Division of Infectious Diseases, MUHC Department of Family Medicine
More informationPrEP Integration into Primary Care
PrEP Integration into Primary Care Linking HIV/AIDS prevention to primary care K A M L A S A N A S I - B H O L A, M D SC Primary Healthcare Association's 23rd Annual Clinical Network Retreat Sunday, June
More informationPrEP Training for Providers in Clinical Settings
PrEP Training for Providers in Clinical Settings Welcome! Please sign the registration sheet. Please make a name tag for yourself. Please take a participant s folder. Any component of this document may
More informationWHO s early release guidelines on PrEP: implications for emtct. Dominika Seidman, MD October 13, 2015
WHO s early release guidelines on PrEP: implications for emtct Dominika Seidman, MD October 13, 2015 Outline Evidence behind WHO early release guidelines on PrEP PrEP eligibility according to the WHO Rationale
More informationClinical Commissioning Policy Proposition: Pre-exposure prophylaxis (PrEP) to prevent the acquisition of HIV in adults
Clinical Commissioning Policy Proposition: Pre-exposure prophylaxis (PrEP) to prevent the acquisition of HIV in adults Reference: NHS England F03X06 First published: TBC Prepared by NHS England Specialised
More informationPre-Exposure Prophylaxis: The New Frontier of Prophylaxis Against HIV Infection
Pre-Exposure Prophylaxis: The New Frontier of Prophylaxis Against HIV Infection William F. Ryan Community Health Network PrEP Network Coordinator: Trevor Hedberg, MPH, CPH Supervising Health Educator:
More informationPrEP 201: Beyond the Basics
NORTHWEST AIDS EDUCATION AND TRAINING CENTER PrEP 201: Beyond the Basics Joanne Stekler, MD MPH Associate Professor of Medicine University of Washington February 19, 2015 Disclosures and Disclaimers I
More informationProfilaxis Antiretroviral para la Prevención de la Infección VIH
1 Profilaxis Antiretroviral para la Prevención de la Infección VIH TAR precoz HIV + en pareja discordante Profilaxis pre exposición (PrEP) Celia Miralles Unidad de VIH H.lXeral Cies (CHUVI) Vigo 2 1 2
More informationHIV Prevention Strategies HIV Pre-exposure prophylaxis
HIV Prevention Strategies HIV Pre-exposure prophylaxis Michael Martin, MD, MPH Director HIV Research Program Thailand MOPH U.S. CDC Collaboration The findings and conclusions in this presentation are those
More informationHIV Clinical Update- HIV prevention
HIV Clinical Update- HIV prevention 18 th Australian and New Zealand Conference on Haemophilia and Rare Bleeding Disorders, Melbourne October 13 th 2017 Edwina Wright Disclosures None in the past 12 months
More informationVictoria Pilkington, Andrew Hill, Sophie Hughes, Nneka Nwokolo and Anton Pozniak. Pilkington et al. Glasgow HIV Poster 0143
Victoria Pilkington, Andrew Hill, Sophie Hughes, Nneka Nwokolo and Anton Pozniak 36.7 Million 1.8 Million 1 Million NEW INFECTIONS LIVING WITH HIV DEATHS https://www.avert.org/global-hiv-and-aids-statistics.
More informationThe HIV Prevention Pill: The State of PrEP Science and Implementation
The HIV Prevention Pill: The State of PrEP Science and Implementation James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE December 11 th, 2014 Overview 1. The Basics 2. A review of the
More informationPre-exposure prophylaxis (PrEP)
FACTSHEET Pre-exposure prophylaxis (PrEP) Summary Pre-exposure prophylaxis, or PrEP, is a way for an HIV-negative person who is at risk of HIV infection to reduce their risk of becoming infected with HIV.
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationPrEP and Behavioral Strategies for HIV Prevention. Douglas Krakower, MD January 30, 2014
PrEP and Behavioral Strategies for HIV Prevention Douglas Krakower, MD January 30, 2014 Potential Competing Interests Dr. Krakower: investigator-initiated research regarding HIV prevention National Institutes
More informationEnding the Epidemic: What Clinicians Need to Know
Ending the Epidemic: What Clinicians Need to Know Mary Goodspeed, RN, BS Coordinator, HIV Clinical Education Erie County Medical Center 716-898-4713 LEARNING OBJECTIVES: 1. List the three points of the
More informationSupplementary Material Table 5. Ongoing PrEP studies among young key population, young people, and key populations. Age range. Study name and location
Supplementary Material Table 5. Ongoing PrEP studies among young key population, young people, and key populations Study name and location ADAPT (HPTN 067) South Africa, Thailand, US (Harlem) Bangkok Tenofovir
More informationPrEP Guidelines for the Ob/Gyn. Outline. 1. How many patient have you discussed PrEP with this year?
PrEP Guidelines for the Ob/Gyn Megan J. Huchko, MD, MPH Obstetrics and Gynecology Update October 14, 2015 I have no financial or other conflicts of interest to declare Outline The Need for PrEP: HIV Treatment
More informationClinical Education Initiative PRE-EXPOSURE PROPHYLAXIS. Speaker: Antonia Urbina, MD
Clinical Education Initiative Support@ceitraining.org PRE-EXPOSURE PROPHYLAXIS Speaker: Antonia Urbina, MD 9/6/2017 Pre-Exposure Prophylaxis [video transcript] 1 00:00:07,480 --> 00:00:09,139 I mean we're
More informationHIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland
HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland An update for registered practitioners November 2017 Rationale for resource This resource is designed to support registered practitioners involved in
More informationThe Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and
More informationHIV Prevention Pearls
HIV Prevention Pearls Meghan Rothenberger, MD Assistant Professor Division of Infectious Diseases University of Minnesota Director, Youth and AIDS Projects October 27, 2017 Disclosure Information I have
More informationPREPARING FOR PrEP: SCIENCE, RESEARCH, AND ACCESS. September 29, :00 PM EST
PREPARING FOR PrEP: SCIENCE, RESEARCH, AND ACCESS September 29, 2016 1:00 PM EST DISCLAIMER This webinar is supported by Cooperative Agreement 5U87PS004223-04 and 5U87PS004164, funded by the Centers for
More informationWhat the Science is Saying: making the case for Treat All
What the Science is Saying: making the case for Treat All CARICOM SECRETARIAT Georgetown, Guyana July 17, 2017 Dr. Shanti Singh- Anthony Knowledge Coordinator PANCAP- Knowledge for Health Project Outline
More informationPre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention
Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention New and Emerging Biomedical HIV Prevention Interventions Vaccines Vaginal microbicides Pre-exposure
More informationGuidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft:
Guidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft: 10-2-2015 Clinical studies demonstrate that when a person without HIV infection takes
More information